Search
Descriptor English: Ado-Trastuzumab Emtansine
Descriptor Spanish: Ado-Trastuzumab Emtansina
Descriptor ado-trastuzumab emtansina
Entry term(s) Kadcyla
conjugado trastumuzab-DM1
huN901-DM1
trastuzumab emtansina
trastuzumab-DM1
Scope note: Inmunotoxina constituida por el anticuerpo monoclonal humanizado anti-HER2 TRASTUZUMAB unido de forma covalente al agente antimicrotubular MAITANSINOIDE DM1 para el tratamiento del cáncer de mama metastásico en pacientes que han recibido previamente trastuzumab y un TAXANO, por separado o en combinación.
Descriptor Portuguese: Ado-Trastuzumab Emtansina
Descriptor French: Ado-trastuzumab emtansine
Entry term(s): Ado Trastuzumab Emtansine
Kadcyla
Trastuzumab DM1
Trastuzumab DM1 Conjugate
Trastuzumab Emtansine
Trastuzumab-DM1
Trastuzumab-DM1 Conjugate
huN901 DM1
huN901-DM1
huN901DM1
Tree number(s): D02.540.505.495.500
D04.345.295.500.500
D12.776.124.486.485.114.224.060.875.500
D12.776.124.790.651.114.224.060.875.500
D12.776.377.715.548.114.224.200.875.500
RDF Unique Identifier: https://id.nlm.nih.gov/mesh/D000080044
Scope note: Immunotoxin that consists of humanized monoclonal anti-HER2 antibody TRASTUZUMAB covalently linked to anti-microtubule agent MAYTANSINOID DM1 for treatment of metastatic breast cancer in patients who previously received trastuzumab and a TAXANES, separately or in combination.
Allowable Qualifiers: AD administration & dosage
AE adverse effects
AN analysis
BL blood
CF cerebrospinal fluid
CH chemistry
CL classification
DE drug effects
EC economics
GE genetics
HI history
IM immunology
IP isolation & purification
ME metabolism
PD pharmacology
PK pharmacokinetics
PO poisoning
RE radiation effects
TO toxicity
TU therapeutic use
UL ultrastructure
UR urine
Pharm Action: Antineoplastic Agents, Immunological
Immunotoxins
Tubulin Modulators
Registry Number: SE2KH7T06F
Public MeSH Note: 2020; ADO-TRASTUZUMAB EMTANSINE was indexed under TRASTUZUMAB and MAYTANSINE 2012-2019 and under ANTIBODIES, MONOCLONAL 2010-2011
History Note: 2020 (2010)
DeCS ID: 59015
Unique ID: D000080044
Documents indexed in the Virtual Health Library (VHL): Click here to access the VHL documents
Date Established: 2020/01/01
Date of Entry: 2019/07/08
Revision Date: 2019/01/16
Ado-Trastuzumab Emtansine - Preferred
Concept UI M0548409
Scope note Immunotoxin that consists of humanized monoclonal anti-HER2 antibody TRASTUZUMAB covalently linked to anti-microtubule agent MAYTANSINOID DM1 for treatment of metastatic breast cancer in patients who previously received trastuzumab and a TAXANES, separately or in combination.
Preferred term Ado-Trastuzumab Emtansine
Entry term(s) Ado Trastuzumab Emtansine
Trastuzumab Emtansine
Kadcyla - Narrower
Concept UI M0581622
Preferred term Kadcyla
huN901-DM1 - Narrower
Concept UI M0493368
Preferred term huN901-DM1
Entry term(s) huN901 DM1
huN901DM1
Trastuzumab-DM1 Conjugate - Narrower
Concept UI M000644821
Preferred term Trastuzumab-DM1 Conjugate
Entry term(s) Trastuzumab DM1
Trastuzumab DM1 Conjugate
Trastuzumab-DM1



We want your feedback on the new DeCS / MeSH website

We invite you to complete a survey that will take no more than 3 minutes.

Go to survey